BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36470820)

  • 1. Evolution of suppressing TSH therapy at diagnosis and in the long-term follow-up in a cohort of differentiated thyroid cancer.
    Díaz-Soto G; Fernández-Velasco P; Torres Torres B; López Gómez JJ; García Calvo S; de Luis Román D
    Endocrinol Diabetes Nutr (Engl Ed); 2022 Dec; 69(10):844-851. PubMed ID: 36470820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
    Park S; Kim WG; Han M; Jeon MJ; Kwon H; Kim M; Sung TY; Kim TY; Kim WB; Hong SJ; Shong YK
    Thyroid; 2017 Sep; 27(9):1164-1170. PubMed ID: 28699428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and dynamic risk stratification in differentiated thyroid cancer in a high-resolution clinic, 2002-2017.
    Díaz-Soto G; Torres BT; López JJ; García S; Quiñones MÁ; de Luis D
    Endocrinol Diabetes Nutr (Engl Ed); 2021 Nov; 68(9):636-641. PubMed ID: 34906344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
    Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
    Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin.
    Mazzaferri EL; Massoll N
    Endocr Relat Cancer; 2002 Dec; 9(4):227-47. PubMed ID: 12542401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and dynamic risk stratification in differentiated thyroid cancer in a high-resolution clinic, 2002-2017.
    Díaz-Soto G; Torres Torres B; López JJ; García S; Álvarez Quiñones M; de Luis D
    Endocrinol Diabetes Nutr (Engl Ed); 2021 Mar; ():. PubMed ID: 33745679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up and results in patients with differentiated thyroid carcinoma in Castilla-La Mancha (2001-2015). The CADIT-CAM study.
    Sastre Marcos J; Aznar S; Álvarez V; Torres B; Delgado M; González J; Quiroga I
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Mar; 66(3):164-172. PubMed ID: 30583968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance of Dynamic Risk Assessment in the Follow-up of Non-distant Metastatic Differentiated Thyroid Cancer Patients with Intermediate and High Risk].
    Liu JR; Liu YQ; Li H; Liang J; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Apr; 42(2):222-227. PubMed ID: 32385029
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
    Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
    Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
    Tuttle RM; Fleisher M; Francis GL; Robbins RJ
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the 2015 American Thyroid Association Risk Stratification System in High-Risk Papillary and Follicular Thyroid Cancer Patients.
    van Velsen EFS; Stegenga MT; van Kemenade FJ; Kam BLR; van Ginhoven TM; Visser WE; Peeters RP
    Thyroid; 2019 Aug; 29(8):1073-1079. PubMed ID: 31140385
    [No Abstract]   [Full Text] [Related]  

  • 12. Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy.
    De Mingo Dominguez ML; Guadalix Iglesias S; Martin-Arriscado Arroba C; López Alvarez B; Martínez Diaz-Guerra G; Martinez-Pueyo JI; Ferrero Herrero E; Hawkins Carranza F
    Endocrine; 2018 Oct; 62(1):166-173. PubMed ID: 30014437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
    Mousa U; Yikilmaz AS; Nar A
    Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors related to mortality in patients with papillary and follicular thyroid cancer in long-term follow-up.
    de Melo TG; Zantut-Wittmann DE; Ficher E; da Assumpção LV
    J Endocrinol Invest; 2014 Dec; 37(12):1195-200. PubMed ID: 25037473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
    Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
    Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
    Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of differentiated thyroid carcinoma: experience in a developing country.
    Bhargav PR; Mishra A; Agarwal G; Agarwal A; Pradhan PK; Gambhir S; Verma AK; Mishra SK
    World J Surg; 2010 Jan; 34(1):40-7. PubMed ID: 20020292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome.
    Lin JD; Hsueh C; Chao TC
    Thyroid; 2009 Oct; 19(10):1053-9. PubMed ID: 19772423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].
    Gemsenjäger E; Heitz PU; Martina B; Schweizer I
    Praxis (Bern 1994); 2000 Nov; 89(44):1779-97. PubMed ID: 11109916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of differentiated thyroid carcinoma staging systems in a Spanish population].
    Andía Melero VM; Martín de Santa-Olalla Llanes M; Sambo Salas M; Percovich Hualpa JC; Motilla de la Cámara M; Collado Yurrita L
    Endocrinol Nutr; 2015 Apr; 62(4):152-60. PubMed ID: 25744071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.